{"id":54850,"date":"2023-03-15T11:05:50","date_gmt":"2023-03-15T10:05:50","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/end-drug-shortages-alliance-releases-report-for-drugs-impacted-by-pharmaceutical-plant-closure\/"},"modified":"2023-03-15T11:05:50","modified_gmt":"2023-03-15T10:05:50","slug":"end-drug-shortages-alliance-releases-report-for-drugs-impacted-by-pharmaceutical-plant-closure","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/end-drug-shortages-alliance-releases-report-for-drugs-impacted-by-pharmaceutical-plant-closure\/","title":{"rendered":"End Drug Shortages Alliance Releases Report for Drugs Impacted by Pharmaceutical Plant Closure"},"content":{"rendered":"
\n

IRVING, Texas–(BUSINESS WIRE)–The End Drug Shortages Alliance<\/a> (EDSA) today released a report assessing the impact to the U.S. market caused by the recent closure of a drug manufacturer. Akorn Pharmaceuticals filed for bankruptcy Feb. 23 and ceased all U.S. manufacturing operations, leaving questions about the impact to the supply of over 100 medications \u2014 some essential \u2014 including injectable and oral products as well as ophthalmic, otic and topical formulations. The full report may be accessed here<\/a>.\n<\/p>\n

<\/a><\/p>\n

\nThe EDSA report, which was a collaborative effort among Vizient, ASHP, and Children\u2019s Hospital Association (CHA), provides an analysis for products with greatest risk of supply disruption and vulnerability, including four essential medications, that, if not available, would prove the greatest threat to a hospital\u2019s ability to provide immediate and high-quality patient care.\n<\/p>\n

\nAs clinicians will need to develop strategies for potential drug shortages, the report offers high-level guidance, including for the impacted essential medications such as adenosine, used in the treatment of supraventricular tachycardia; calcitriol, used to manage hyperparathyroidism in patients undergoing renal dialysis; dimercaprol, an antidote for metal poisoning; mycophenolate mofetil, a prophylaxis for organ rejection; and physostigmine, used in the reversal of anticholinergic syndrome.\n<\/p>\n

\n\u201cTransparency regarding drug shortages is important to ensure patient care remains uninterrupted,\u201d said Mittal Sutaria, senior vice president, Vizient pharmacy contract and program services and EDSA board member. \u201cThe healthcare system needs time so that pharmaceutical companies can increase manufacturing when possible and providers can develop mitigation strategies to alleviate any potential disruption in supply when a manufacturer exits the market.\u201d\n<\/p>\n

\nThe report assesses data from multiple sources including essential medication status, market share and current ASHP shortage designation to estimate the resilience of a particular product. It also offers recommendations for key stakeholders, including:\n<\/p>\n